December 3, 2019
Axovant Announces Amendment to Credit Facility with Hercules Capital
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced the completion of an amendment to its loan and security agreement ...
December 3, 2019
Genkyotex Reports Progress of Setanaxib Phase 2 Investigator Initiated Trials
ARCHAMPS, France, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, ...
December 3, 2019
Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment
HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today ...
December 3, 2019
Celyad Announces Board of Directors Evolution with New Appointment
Celyad (CYAD.BR) (CYAD.BR) (CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that Filippo Petti, CEO of Celyad, is ...
December 3, 2019
MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers
YAVNE, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the “Company”) (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in ...
December 3, 2019
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
DUBLIN, Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase ...
December 3, 2019
Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has submitted an Investigational New Drug ...
December 3, 2019
Cidara Therapeutics to Present at Two Upcoming Medical Conferences
SAN DIEGO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will ...
December 3, 2019
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
VANCOUVER, Washington, Dec. 03, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ...
December 3, 2019
HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on the Future of Precision Medicine
TUCSON, Ariz., Dec. 03, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, ...
December 3, 2019
Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010
CRANBURY, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ...
December 3, 2019
Inventiva receives a €3.5 m milestone payment from AbbVie
Daix (France), December 3, 2019 – Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
November 25, 2019
Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)
MILAN--(BUSINESS WIRE)--Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the ...
November 25, 2019
CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study
MONMOUTH JUNCTION, N.J., Nov. 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) is temporarily pausing enrollment of its REFRESH 2-AKI study at the recommendation of its Data Monitoring Committee (DMC) ...
November 25, 2019
BrainsWay Reports Third Quarter 2019 Financial Results and Operational Highlights
JERUSALEM, Israel and HACKENSACK, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in ...
November 25, 2019
FDA Accepts Intercept’s NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...
November 25, 2019
TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced it will ...
November 25, 2019
Beyond Air Signs Agreement with MESA Specialty Gases & Equipment for Nitric Oxide and Nitrogen Dioxide Calibration Gas Supply
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused ...
November 25, 2019
Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
DUBLIN, Ireland, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for ...
November 25, 2019
NeuBase Therapeutics to Present at Upcoming Investor Conferences in December
PITTSBURGH, Nov. 25, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address ...
Page 37 of 176